Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
TFG
REST API REST API
Homo sapiens
TFG is differentially expressed in 243 experiments: 116 organism parts: placenta, liver, ... (114 more);, 207 disease states: normal, benign prostatic hyperplasia, ... (205 more);, 78 cell types 279 cell lines 35 compound treatments and 72 other conditions.
Synonyms TF6, FLJ36137
Orthologs ENSBTAG00000016363 (Bos taurus)   tfg (Danio rerio)   TFG (Gallus gallus)   ENSCING00000004004 (Ciona intestinalis)   Tfg (Mus musculus)   Tfg (Rattus norvegicus)   tfg (Xenopus laevis)   ENSBTAG00000045493 (Bos taurus)   TFG (Canis familiaris)   (Compare orthologs)
Gene Ontology Term protein binding, cytoplasm, signal transducer activity, identical protein binding, signal transduction, positive regulation of I-kappaB kinase/NF-kappaB cascade
InterPro Term OPR_PB1
UniProt Accession Q92734, C9JJP5, C9JTY3, C9JUE0, Q7Z427, Q05BK6
Gene-Disease Assocation CHONDROSARCOMA, EXTRASKELETAL MYXOID, THYROID CARCINOMA, PAPILLARY
Search EB-eye ENSG00000114354
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-AFMX-5, E-GEOD-6573, E-GEOD-22541, E-MTAB-24, ... (21 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, E-GEOD-18005, ... (36 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-19639, E-GEOD-3529, E-GEOD-20081, E-GEOD-5823
SW480
3
E-MEXP-1014, E-GEOD-18005, E-MTAB-37
BT20
2
E-MTAB-62, E-MTAB-37
BT474
2
E-MEXP-440, E-MTAB-62
CCRFCEM
2
E-GEOD-24147, E-MTAB-37
MOLT4
2
E-MTAB-62, E-MTAB-37
273 more value(s).


Cell type

studied in E-GEOD-21668, E-MEXP-993, E-GEOD-4219, E-GEOD-20677, E-GEOD-13909, ... (36 experiments)

Factor Value U/D Experiments
721 B lymphoblast
2
E-AFMX-5, E-TABM-145
alveolar space neutrophil
1
E-GEOD-2322
leydig cell
1
E-MTAB-25
mast cell
1
E-GEOD-3982
CD326negCD56+ cell
1
E-GEOD-21668
monolayer recovery
1
E-GEOD-4219
72 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-MEXP-1121, E-MEXP-2280, E-MTAB-680, ... (49 experiments)

Factor Value U/D Experiments
cervical carcinoma
2
E-MTAB-62, E-MEXP-1331
prostate carcinoma
2
E-MEXP-2034, E-MTAB-62
rhabdomyosarcoma
2
E-MTAB-62, E-MTAB-37
benign prostatic hyperplasia
1
2
E-MEXP-2034, E-MEXP-1243, E-GEOD-5377
chronic myelogenous leukemia
1
2
E-MTAB-62, E-GEOD-5550, E-MTAB-37
mock infected
1
E-MEXP-1072
201 more value(s).


Compound treatment

studied in E-GEOD-6907, E-GEOD-15205, E-GEOD-1417, E-GEOD-5824, E-TABM-868, ... (21 experiments)

Factor Value U/D Experiments
none
3
4
E-GEOD-5824, E-MEXP-1958, E-MEXP-1601, E-GEOD-6907, E-TABM-868, ... (7 experiments)
sapphyrin PCI-2055
1
E-GEOD-6400
placebo
1
E-MEXP-1337
FCCP
1
1
E-MEXP-2285
5-aza-2'-deoxycytidine
2
1
E-MEXP-1269
interleukin-4 (Homo sapiens)
1
E-GEOD-5099
29 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


Biosource provider
studied in E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, ... (6 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-17189, E-GEOD-19348, E-GEOD-21589, ... (8 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532, E-GEOD-21610

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-5999, E-GEOD-20033, E-GEOD-3140, E-MEXP-2359, ... (7 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-7788, E-GEOD-22148, E-GEOD-21138, E-GEOD-19665 ... (5 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-1643, E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, E-GEOD-20847, ... (7 experiments)

Genotype
studied in E-TABM-763, E-TABM-1029, E-GEOD-3494, E-GEOD-17476, E-GEOD-22593, ... (10 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-MEXP-1220, E-GEOD-5681, E-GEOD-20540, E-MEXP-1103, E-MEXP-1273 ... (5 experiments)

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Individual
studied in E-MTAB-197, E-TABM-325, E-TABM-740, E-MEXP-2069, E-GEOD-16363, ... (26 experiments)

Infection
studied in E-GEOD-12108, E-GEOD-12254, E-MEXP-561

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214, E-GEOD-22056

Ki67 ihc
studied in E-GEOD-21653

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-TABM-84

Organism status
studied in E-GEOD-19188

Phenotype
studied in E-GEOD-21750, E-GEOD-1657, E-GEOD-17636

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-18791, E-GEOD-10896

Rna integrity
studied in E-TABM-325

RNAi
studied in E-GEOD-12438, E-MEXP-101, E-GEOD-3697, E-MEXP-1857

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-17400, E-GEOD-18995

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-7307

Stimulation
studied in E-GEOD-13909, E-GEOD-20114, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-4922, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Treatment
studied in E-GEOD-19246, E-GEOD-13818, E-GEOD-19815, E-GEOD-12198

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Ttf
studied in E-GEOD-21521

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-1561, E-GEOD-6532, E-GEOD-4922 ... (5 experiments)

Tumor size
studied in E-GEOD-6532

Vehicle
studied in E-GEOD-5258

Processing time: 0.403 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM